Asymmetric Synthesis of Chiral Primary Amines by Ruthenium-Catalyzed Direct Reductive Amination of Alkyl Aryl Ketones with Ammonium Salts and Molecular H<sub>2</sub>
amination of simple ketones. The strategy makes use of ammonium acetate as the amine source and H2 as the reductant and is a user-friendly and operatively simple access to industrially relevant primary amines. Excellent enantiocontrol (>90% ee for most cases) was achieved with a wide range of alkylarylketones. The practicability of this methodology has been highlighted by scalable synthesis of key intermediates
[EN] COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS
申请人:XIOS THERAPEUTICS INC
公开号:WO2020106625A1
公开(公告)日:2020-05-28
The present invention features compounds useful in the treatment of adenosine or adenosine receptor related disorders.
本发明涉及在治疗腺苷或腺苷受体相关疾病中有用的化合物。
1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use
申请人:Askew C. Benny
公开号:US20060025400A1
公开(公告)日:2006-02-02
Selected compounds are effective for treatment of pain and diseases, such as inflammation mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving pain, inflammation, and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
Chiral ruthenium(II) complexes, RuCl2(PPh3)(oxazolinylferrocenylphosphine), have been found to be effective catalysts for asymmetrichydrosilylation of ketoximes to give the corresponding primary amines in good yields with high enantioselectivities (up to 89% ee) after acid hydrolysis.